[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340634-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340634-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","can-molecular-patterns-help-to-classify-overlapping-entities-in-myeloid-neoplasms-review","Can molecular patterns help to classify overlapping entities in myeloid neoplasms? - review","","Molecular patterns are evaluated as tools to resolve diagnostic overlap among myeloid neoplasms, which include myeloproliferative and myelodysplastic disorders and acute myeloid leukemia. Despite improved classification using combined clinicopathological and molecular features, persistent overlap creates challenges, such as BCR::ABL1-negative MPN conflicts, boundaries between clonal cytopenia of undetermined significance and myelodysplastic neoplasms, and KIT mutations outside mastocytosis. The review considers how molecular testing and future whole-genome/transcriptome data could support classification frameworks grounded in genetic groups while clinicopathological traits describe disease stage rather than specific entity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/can-molecular-patterns-help-to-classify-overlapping-entities-in-myeloid-neoplasms-review/340634/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/can-molecular-patterns-help-to-classify-overlapping-entities-in-myeloid-neoplasms-review/340634.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which myeloid neoplasms and overlaps does the review focus on?","Question",{"text":63,"@type":64},"It addresses myeloproliferative and myelodysplastic neoplasms and acute myeloid leukemia, highlighting overlap such as BCR::ABL1-negative MPN, the boundary between CCUS and MDS, MDS/MPN overlap, and KIT mutations outside mastocytosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why do diagnostic overlaps persist even with current molecular approaches?",{"text":68,"@type":64},"Although most cases can be classified accurately using molecular plus clinicopathological features, some molecular characteristics are non-specific and remain sensitive to context, leaving certain scenarios difficult.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the review propose molecular testing should be used going forward?",{"text":72,"@type":64},"It suggests molecular testing will expand toward whole-genome and transcriptome sequencing, with genetically defined groups forming the basis for understanding disease development, while clinicopathological features help describe disease stage.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340634,1790182094,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Histopathology 2025, 86, 146–157. DOI: 10.1111/his.15339  \nREVIEW  \nCan molecular patterns help to classify overlapping entities in myeloid neoplasms?  \nGregor Hoermann 1 & Joseph D Khoury2  \n1MLL Munich Leukemia Laboratory, Munich, Germany and 2Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, USA  \nHoermann G & Khoury J D  \n(2025) Histopathology 86, 146–157. [https://doi.org/10.1111/his.15339](https://doi.org/10.1111/his.15339)  \nCan molecular patterns help to classify overlapping entities in myeloid neoplasms?  \nMyeloid neoplasms include myeloproliferative and myelodysplastic neoplasms and acute myeloid leukaemia. Historically, these diseases have been diagnosed based on clinicopathological features with sometimes arbitrary thresholds that have persisted even as molecular features were gradually incorporated into their classiﬁcation. As such, although current diagnostic approaches can classify the majority of myeloid neoplasms accurately using a combination of molecular and clinicopathological features, some areas of overlap persist and occasionally pose diagnostic challenges. These include overlap across BCR::ABL1-negative myeloproliferative neoplasms; between clonal cytopenia of undetermined signiﬁcance and myelodysplastic neoplasms; myelodysplastic/myeloproliferative neoplasms; and, detection of KIT mutations in myeloid  \nneoplasms other than mastocytosis, raising the prospect of systemic mastocytosis. Molecular testing has become state of the art in the diagnostic work-up of myeloid neoplasms, and molecular patterns can inherently help to classify overlapping entities if considered within a framework of haematological presentations. For future development, molecular testing will likely include whole genome and transcriptome sequencing, and primarily molecular classiﬁcations of myeloid neoplasms have already been suggested. As such, genetically deﬁned groups should still constitute the basis for our understanding of disease development from early onset to progression, while clinicopathological features could then be used to describe the stage of the disease rather than the speciﬁc typeof myeloid neoplasm.  \nKeywords: chronic myelomonocytic leukaemia, disease classiﬁcation, genetics, molecular patterns, myelodysplastic neoplasms, myeloid neoplasms, myeloproliferative neoplasms, systemic mastocytosis  \nAddress for correspondence: J D Khoury, Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA. e-mail: [jkhoury@unmc.edu](jkhoury@unmc.edu)  \nAbbreviations: AML, acute myeloid leukemia; BM, bone marrow; CCMUS, clonal cytopenia and monocytosis of undetermined signiﬁcance; CCUS, clonal cytopenia of undetermined signiﬁcance; CH, clonal hematopoiesis; CHIP, clonal hematopoiesis of indeterminate potential; CHRS, clonal haematopoiesis risk score; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CMUS, clonal monocytosis of undetermined signiﬁcance; CNL, chronic neutrophilic leukemia; ET, essential thrombocythemia; ICC, international consensus classiﬁcation; IPSS, international prognostic scoring system; IPSS-M, molecular IPSS; IPSS-R, revised IPSS; MDS, myelodysplastic neoplasm; MDS/MPN, myelodysplastic/myeloproliferative neoplasms; MDS/MPN-N, MDS/MPN with neutrophilia; MDS/MPN-SF3B1-T, MDS/MPN with SF3B1 mutation and thrombocytosis; MDS-5q, MDS with low blasts and 5q deletion; MDS-biTP53, MDS with biallelic TP53 inactivation; MDS-SF3B1, MDS with low blasts and SF3B1 mutation; MPN, myeloproliferative neoplasm; PMF, primary myeloﬁbrosis; Pre-PMF, preﬁbrotic/early stage PMF; PV, polycythemia vera; SM, systemic mastocytosis; SM-AHN, SM with an associated hematologic neoplasm; WHO, world health organization; WHO-HAEM5, 5th edition of the WHO classiﬁcation of hematolymphoid neoplasms.  \n􀀁 2024 The Author(s) . Histopathology published by John Wiley & Sons Ltd.  \nThis is ","cbCaiaX5CAwlmAEl","https://ap.wps.com/l/cbCaiaX5CAwlmAEl","pdf",1146416,12,"English","# Introduction\n## Overview of the elements underpinning myeloid neoplasm classification","[{\"question\":\"Which myeloid neoplasms and overlaps does the review focus on?\",\"answer\":\"It addresses myeloproliferative and myelodysplastic neoplasms and acute myeloid leukemia, highlighting overlap such as BCR::ABL1-negative MPN, the boundary between CCUS and MDS, MDS/MPN overlap, and KIT mutations outside mastocytosis.\"},{\"question\":\"Why do diagnostic overlaps persist even with current molecular approaches?\",\"answer\":\"Although most cases can be classified accurately using molecular plus clinicopathological features, some molecular characteristics are non-specific and remain sensitive to context, leaving certain scenarios difficult.\"},{\"question\":\"How does the review propose molecular testing should be used going forward?\",\"answer\":\"It suggests molecular testing will expand toward whole-genome and transcriptome sequencing, with genetically defined groups forming the basis for understanding disease development, while clinicopathological features help describe disease stage.\"}]","Can molecular patterns help to classify overlapping entities in myeloid neoplasms? - review | PDF",1790037821,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85e0fa835f2d3adc528550a12eefc041.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8466000405d72bd0172465b125800e20.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e744dc71cbfc84a7dc464550231e657.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48e369f74aa47f8a5bd88bb50dd07ed4.webp",980,1287]